T Cells clinical trials

Golcadomide and rituximab before CAR T for lymphoma

This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.

T-cell lymphoma registry study

This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.

Remote hearing test for head and neck cancer patients on cisplatin or radiation

This study tests a remote hearing test to monitor hearing changes in patients with head and neck cancer getting cisplatin chemotherapy and/or radiation. The goal is to catch hearing loss early so treatment can be adjusted.

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

Immunotherapy plus a targeted drug for rare genitourinary tumors

This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.

Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma

This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.

Robot-assisted mouth and throat surgery for head and neck tumors

This trial studies using a robot-assisted operation through the mouth to diagnose or treat certain non-cancer (benign) and cancer (malignant) tumors in the head and neck. It may help some people avoid more invasive surgery by using an approach that reaches the throat and voice box area through the mouth.

Testing cetuximab plus pembrolizumab for advanced head and neck cancer

This trial tests whether adding cetuximab to the standard drug pembrolizumab works better for head and neck cancer that has spread or come back after treatment. It is for people whose cancer did not respond to platinum chemotherapy and whose tumors have a certain immune marker (PD-L1).

TMV vaccine alone or with pembrolizumab for advanced HNSCC

This trial tests a vaccine made from your own tumor to help your immune system fight head and neck cancer that has returned or spread. It is given alone or with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors or slow progression.

Tegavivint for relapsed or hard-to-treat lymphoma patients

This Phase 1 trial tests tegavivint, a new investigational medicine, for certain types of aggressive B-cell lymphoma that have come back or did not respond to prior treatment. It may help shrink the lymphoma and learn how safe and effective the drug is in this setting.

Testing camonsertib with radiation for returning head and neck cancer

This study tests whether adding the drug camonsertib to radiation therapy can help people whose head and neck cancer has come back in a spot that was already treated with radiation. Camonsertib is an experimental drug that may help radiation work better.

Nivolumab at home vs. clinic for cancer treatment

This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.

Lovastatin plus pembrolizumab for advanced head and neck cancer

This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.

Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma

This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.

Study of a new drug for advanced kidney cancer

This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.

Odronextamab before CAR-T for large B-cell lymphoma

This trial tests a drug called odronextamab for people with large B-cell lymphoma whose cancer did not respond to or came back after initial treatment. The goal is to see if odronextamab can help shrink the tumor before getting CAR-T cell therapy.

CCR4 CAR T cells for T-cell lymphoma

This trial tests a new immunotherapy that targets a protein called CCR4 on certain T-cell lymphomas. The treatment uses your own immune cells, modified to find and attack cancer cells, and may help when other treatments have stopped working.

Vaccine plus immune drugs for relapsed blood cancers

This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.

SynKIR-310 for advanced B-cell lymphoma

This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.

Epcoritamab with chemo before stem cell transplant for DLBCL

This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.

Testing two immunotherapy drugs before surgery for advanced head and neck cancer

This trial tests whether adding a second immunotherapy drug (CDX-1140) to the standard immunotherapy cemiplimab before surgery is better than cemiplimab alone for people with stage III-IV head and neck cancer that can be removed with surgery.

Study of CC-99282 plus rituximab after CAR-T for lymphoma

This trial tests combining an experimental pill (CC-99282) with the immunotherapy drug rituximab for people with B-cell non-Hodgkin's lymphoma whose cancer did not fully respond to CAR-T cell therapy. The goal is to improve results after CAR-T.

ST-067 with CAR T-cell therapy for large B-cell lymphoma

This trial tests a new drug, ST-067, combined with a CAR T-cell therapy (liso-cel) for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments. The goal is to see if the combination is safe and effective.

Cabozantinib plus nivolumab for advanced melanoma or head-neck cancer

This trial tests whether combining two immunotherapy medicines—cabozantinib and nivolumab—can shrink advanced melanoma or certain head-and-neck squamous cell cancers. It is mainly for people whose cancer has grown after prior PD-1 treatment.